Header Logo

Connection

Gary Raskob to Humans

Back to Details
This is a "connection" page, showing publications Gary Raskob has written about Humans.
Gary Raskob
Connection Strength
2.221
Humans
  1. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 Nov 29; 406(10519):2551-2563.
    View in: PubMed
    Score: 0.054
  2. Anticoagulant Therapy for Mechanical Heart Valves - Unmet Need Persists. NEJM Evid. 2023 Jul; 2(7):EVIDe2300106.
    View in: PubMed
    Score: 0.046
  3. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 10 18; 11(20):e026229.
    View in: PubMed
    Score: 0.044
  4. Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost. 2022 10; 20(10):2366-2378.
    View in: PubMed
    Score: 0.043
  5. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.
    View in: PubMed
    Score: 0.041
  6. Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. J Am Heart Assoc. 2021 02; 10(5):e019459.
    View in: PubMed
    Score: 0.039
  7. Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thromb Haemost. 2021 Jun; 121(6):816-825.
    View in: PubMed
    Score: 0.039
  8. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16.
    View in: PubMed
    Score: 0.038
  9. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 06 30; 75(25):3140-3147.
    View in: PubMed
    Score: 0.037
  10. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thromb Haemost. 2020 Jun; 120(6):924-936.
    View in: PubMed
    Score: 0.037
  11. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139.
    View in: PubMed
    Score: 0.036
  12. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb Res. 2020 01; 185:13-19.
    View in: PubMed
    Score: 0.036
  13. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
    View in: PubMed
    Score: 0.035
  14. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.
    View in: PubMed
    Score: 0.034
  15. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
    View in: PubMed
    Score: 0.033
  16. Edoxaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 07 05; 379(1):95-96.
    View in: PubMed
    Score: 0.032
  17. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
    View in: PubMed
    Score: 0.031
  18. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 08 30; 117(9):1662-1670.
    View in: PubMed
    Score: 0.030
  19. The Value of Prevention Research Centers: Breaking New Ground in Prevention Research. Am J Prev Med. 2017 03; 52(3 Suppl 3):S214-S215.
    View in: PubMed
    Score: 0.030
  20. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug; 3(8):e379-87.
    View in: PubMed
    Score: 0.028
  21. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016 Apr 29; 118(9):1340-7.
    View in: PubMed
    Score: 0.028
  22. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36.
    View in: PubMed
    Score: 0.028
  23. Global public awareness of venous thromboembolism: reply. J Thromb Haemost. 2016 05; 14(5):1111-2.
    View in: PubMed
    Score: 0.028
  24. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8.
    View in: PubMed
    Score: 0.027
  25. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16.
    View in: PubMed
    Score: 0.027
  26. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10.
    View in: PubMed
    Score: 0.027
  27. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25; 114(6):1268-76.
    View in: PubMed
    Score: 0.027
  28. The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. Am Heart J. 2015 Sep; 170(3):447-54.e18.
    View in: PubMed
    Score: 0.026
  29. On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4.
    View in: PubMed
    Score: 0.025
  30. On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4.
    View in: PubMed
    Score: 0.025
  31. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2363-71.
    View in: PubMed
    Score: 0.025
  32. Oral anticoagulants: new and improved. Blood. 2014 Sep 18; 124(12):1851-2.
    View in: PubMed
    Score: 0.025
  33. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30.
    View in: PubMed
    Score: 0.024
  34. Importance of subsegmental pulmonary embolism. Blood. 2013 Aug 15; 122(7):1094-5.
    View in: PubMed
    Score: 0.023
  35. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
    View in: PubMed
    Score: 0.023
  36. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64.
    View in: PubMed
    Score: 0.021
  37. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
    View in: PubMed
    Score: 0.019
  38. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr; 38(4 Suppl):S502-9.
    View in: PubMed
    Score: 0.018
  39. Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800.
    View in: PubMed
    Score: 0.016
  40. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med. 2007 Oct; 120(10):901.e1-13.
    View in: PubMed
    Score: 0.015
  41. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13; 357(11):1094-104.
    View in: PubMed
    Score: 0.015
  42. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12.
    View in: PubMed
    Score: 0.015
  43. Injury prevention and control research and training in accredited schools of public health: a CDC/ASPH assessment. Public Health Rep. 2006 May-Jun; 121(3):349-51.
    View in: PubMed
    Score: 0.014
  44. Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial. Ann Intern Med. 2004 Dec 07; 141(11):839-45.
    View in: PubMed
    Score: 0.013
  45. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):401S-428S.
    View in: PubMed
    Score: 0.012
  46. Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004 Mar; 125(3):851-5.
    View in: PubMed
    Score: 0.012
  47. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20.
    View in: PubMed
    Score: 0.012
  48. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S.
    View in: PubMed
    Score: 0.012
  49. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec; 124(6 Suppl):393S-396S.
    View in: PubMed
    Score: 0.012
  50. Helical computed tomography and magnet resonance imaging: diagnosis of pulmonary embolism in symptomatic patients. Curr Opin Hematol. 2003 Sep; 10(5):345-50.
    View in: PubMed
    Score: 0.012
  51. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 04 07; 44(14):1231-1244.
    View in: PubMed
    Score: 0.011
  52. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8.
    View in: PubMed
    Score: 0.011
  53. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003; 21(7):477-96.
    View in: PubMed
    Score: 0.011
  54. Redefining clinical venous thromboembolism phenotypes: a?novel approach using latent class analysis. J Thromb Haemost. 2023 03; 21(3):573-585.
    View in: PubMed
    Score: 0.011
  55. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.
    View in: PubMed
    Score: 0.011
  56. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med. 2002 Feb 25; 162(4):401-4.
    View in: PubMed
    Score: 0.010
  57. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001 Nov 20; 135(10):858-69.
    View in: PubMed
    Score: 0.010
  58. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
    View in: PubMed
    Score: 0.010
  59. Abelacimab for Prevention of Venous Thromboembolism. Reply. N Engl J Med. 2021 11 04; 385(19):1822-1823.
    View in: PubMed
    Score: 0.010
  60. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 10; 174(10):1420-1429.
    View in: PubMed
    Score: 0.010
  61. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 12; 19(12):3008-3017.
    View in: PubMed
    Score: 0.010
  62. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60.
    View in: PubMed
    Score: 0.010
  63. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 11; 19(11):2801-2813.
    View in: PubMed
    Score: 0.010
  64. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780.
    View in: PubMed
    Score: 0.010
  65. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
    View in: PubMed
    Score: 0.010
  66. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211053316.
    View in: PubMed
    Score: 0.010
  67. Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med. 2000 Sep; 109(4):301-6.
    View in: PubMed
    Score: 0.009
  68. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J. 2020 02; 55(2).
    View in: PubMed
    Score: 0.009
  69. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524.
    View in: PubMed
    Score: 0.009
  70. Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thromb Res. 2019 Dec; 184:58-61.
    View in: PubMed
    Score: 0.009
  71. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
    View in: PubMed
    Score: 0.009
  72. Diagnosis of pulmonary embolism. Curr Opin Hematol. 1999 Sep; 6(5):280-4.
    View in: PubMed
    Score: 0.009
  73. The evidence-based analysis of treatment for chronic myeloid leukemia: An introduction to its methods and clinical implications. Blood. 1999 Sep 01; 94(5):1515-6.
    View in: PubMed
    Score: 0.009
  74. Heparin and low molecular weight heparin for treatment of acute pulmonary embolism. Curr Opin Pulm Med. 1999 Jul; 5(4):216-21.
    View in: PubMed
    Score: 0.009
  75. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
    View in: PubMed
    Score: 0.008
  76. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
    View in: PubMed
    Score: 0.008
  77. Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 12 06; 379(23):2280.
    View in: PubMed
    Score: 0.008
  78. Hirudin versus heparin and low-molecular-weight heparin: and the winner is... J Lab Clin Med. 1998 Sep; 132(3):171-4.
    View in: PubMed
    Score: 0.008
  79. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
    View in: PubMed
    Score: 0.008
  80. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 10; 170:75-83.
    View in: PubMed
    Score: 0.008
  81. Idiopathic thrombocytopenic purpura: diagnosis and management. Am J Med Sci. 1998 Aug; 316(2):87-93.
    View in: PubMed
    Score: 0.008
  82. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
    View in: PubMed
    Score: 0.008
  83. Different effects of heparin in males and females. Clin Invest Med. 1998 Apr; 21(2):71-8.
    View in: PubMed
    Score: 0.008
  84. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med. 1998 Feb; 30(1):38-44.
    View in: PubMed
    Score: 0.008
  85. Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 01; 118(1):174-181.
    View in: PubMed
    Score: 0.008
  86. Idiopathic thrombocytopenic purpura: A concise summary of the pathophysiology and diagnosis in children and adults. Semin Hematol. 1998 Jan; 35(1 Suppl 1):5-8.
    View in: PubMed
    Score: 0.008
  87. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis. 1998; 28 Suppl 3:8-16.
    View in: PubMed
    Score: 0.008
  88. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14.
    View in: PubMed
    Score: 0.008
  89. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
    View in: PubMed
    Score: 0.008
  90. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. Thromb Haemost. 2017 Oct; 117(10):1944-1951.
    View in: PubMed
    Score: 0.008
  91. Thrombotic complications of antithrombotic therapy: a paradox with implications for clinical practice. Ann Intern Med. 1997 Nov 01; 127(9):839-41.
    View in: PubMed
    Score: 0.008
  92. Clinical decisions in idiopathic thrombocytopenic purpura. Hosp Pract (1995). 1997 Sep 15; 32(9):159-60, 163-6, 169-70, passim.
    View in: PubMed
    Score: 0.008
  93. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017 10 05; 117(10):1944-1951.
    View in: PubMed
    Score: 0.008
  94. Duration of anticoagulant treatment for venous thrombosis. Curr Opin Pulm Med. 1997 Jul; 3(4):286-90.
    View in: PubMed
    Score: 0.008
  95. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 04 03; 117(4):784-793.
    View in: PubMed
    Score: 0.007
  96. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421.
    View in: PubMed
    Score: 0.007
  97. Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6.
    View in: PubMed
    Score: 0.007
  98. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45.
    View in: PubMed
    Score: 0.007
  99. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164.
    View in: PubMed
    Score: 0.007
  100. Oral anticoagulant therapy. Curr Opin Hematol. 1996 Sep; 3(5):361-4.
    View in: PubMed
    Score: 0.007
  101. Pulmonary embolism among patients with a nearly normal ventilation/perfusion lung scan. Chest. 1996 Aug; 110(2):395-8.
    View in: PubMed
    Score: 0.007
  102. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27; 116(4):747-53.
    View in: PubMed
    Score: 0.007
  103. Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Curr Opin Pulm Med. 1996 Jul; 2(4):305-10.
    View in: PubMed
    Score: 0.007
  104. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res. 2016 07 01; 76(13):3671-5.
    View in: PubMed
    Score: 0.007
  105. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. Chest. 2016 Nov; 150(5):1059-1068.
    View in: PubMed
    Score: 0.007
  106. The US Cancer Moonshot initiative. Lancet Oncol. 2016 05; 17(5):e178-80.
    View in: PubMed
    Score: 0.007
  107. Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60.
    View in: PubMed
    Score: 0.007
  108. Diversity and severity of adverse reactions to quinine: A systematic review. Am J Hematol. 2016 May; 91(5):461-6.
    View in: PubMed
    Score: 0.007
  109. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 07 04; 116(1):155-61.
    View in: PubMed
    Score: 0.007
  110. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91.
    View in: PubMed
    Score: 0.007
  111. Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol. 1995 Sep; 2(5):372-9.
    View in: PubMed
    Score: 0.007
  112. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71.
    View in: PubMed
    Score: 0.007
  113. Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
    View in: PubMed
    Score: 0.007
  114. Anticoagulants and thrombolysis in the treatment of pulmonary embolism. Curr Opin Pulm Med. 1995 Jul; 1(4):291-7.
    View in: PubMed
    Score: 0.007
  115. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 01; 85(11):3034-9.
    View in: PubMed
    Score: 0.007
  116. Impedance plethysmography for suspected deep-vein thrombosis. Arch Intern Med. 1995 Apr 10; 155(7):773, 776.
    View in: PubMed
    Score: 0.006
  117. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40.
    View in: PubMed
    Score: 0.006
  118. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994 Nov 03; 331(18):1207-11.
    View in: PubMed
    Score: 0.006
  119. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med. 1994 Sep 01; 121(5):313-7.
    View in: PubMed
    Score: 0.006
  120. Treatment of venous thromboembolism. Curr Opin Hematol. 1994 Sep; 1(5):329-35.
    View in: PubMed
    Score: 0.006
  121. Preventing systemic embolism in patients with abnormal ventricular function. Cardiol Clin. 1994 Aug; 12(3):477-85.
    View in: PubMed
    Score: 0.006
  122. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15.
    View in: PubMed
    Score: 0.006
  123. Impedance plethysmography and DVT diagnosis. Ann Intern Med. 1993 Aug 01; 119(3):247.
    View in: PubMed
    Score: 0.006
  124. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
    View in: PubMed
    Score: 0.006
  125. Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2013 Apr; 32(2):111-260.
    View in: PubMed
    Score: 0.006
  126. Long-term oral anticoagulant therapy for coronary artery disease. Haemostasis. 1993 Mar; 23 Suppl 1:32-41.
    View in: PubMed
    Score: 0.006
  127. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51.
    View in: PubMed
    Score: 0.006
  128. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708.
    View in: PubMed
    Score: 0.006
  129. Hemorrhagic complications of anticoagulant treatment. Chest. 1992 Oct; 102(4 Suppl):352S-363S.
    View in: PubMed
    Score: 0.005
  130. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04 05; 366(14):1287-97.
    View in: PubMed
    Score: 0.005
  131. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012 Feb 11; 379(9815):537-46.
    View in: PubMed
    Score: 0.005
  132. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9.
    View in: PubMed
    Score: 0.005
  133. Venous thromboembolic disease. Curr Opin Cardiol. 1991 Oct; 6(5):750-6.
    View in: PubMed
    Score: 0.005
  134. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036.
    View in: PubMed
    Score: 0.005
  135. Low-probability lung scan findings: a need for change. Ann Intern Med. 1991 Jan 15; 114(2):142-3.
    View in: PubMed
    Score: 0.005
  136. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
    View in: PubMed
    Score: 0.005
  137. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
    View in: PubMed
    Score: 0.005
  138. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
    View in: PubMed
    Score: 0.005
  139. Diagnosis and management of pulmonary thromboembolism. Q J Med. 1990 Aug; 76(280):787-97.
    View in: PubMed
    Score: 0.005
  140. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37.
    View in: PubMed
    Score: 0.005
  141. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost. 2010 Jul; 104(1):86-91.
    View in: PubMed
    Score: 0.005
  142. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15.
    View in: PubMed
    Score: 0.005
  143. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87.
    View in: PubMed
    Score: 0.004
  144. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604.
    View in: PubMed
    Score: 0.004
  145. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3.
    View in: PubMed
    Score: 0.004
  146. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 07; 7:30.
    View in: PubMed
    Score: 0.004
  147. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
    View in: PubMed
    Score: 0.004
  148. Anticoagulant therapy for venous thromboembolism. Prog Hemost Thromb. 1989; 9:1-27.
    View in: PubMed
    Score: 0.004
  149. Heparin therapy for venous thrombosis and pulmonary embolism. Blood Rev. 1988 Dec; 2(4):251-8.
    View in: PubMed
    Score: 0.004
  150. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug; 83(8):923-31.
    View in: PubMed
    Score: 0.004
  151. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7.
    View in: PubMed
    Score: 0.004
  152. Challenges in the diagnosis of acute pulmonary embolism. Am J Med. 2008 Jul; 121(7):565-71.
    View in: PubMed
    Score: 0.004
  153. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):454S-545S.
    View in: PubMed
    Score: 0.004
  154. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
    View in: PubMed
    Score: 0.004
  155. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 01; 25(34):5490-505.
    View in: PubMed
    Score: 0.004
  156. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007 Jun; 5(6):1191-4.
    View in: PubMed
    Score: 0.004
  157. Frequency of a normal lung scan observed in the urokinase-streptokinase pulmonary embolism trial. Invest Radiol. 1987 Apr; 22(4):357.
    View in: PubMed
    Score: 0.004
  158. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007 Jan; 120(1):72-82.
    View in: PubMed
    Score: 0.004
  159. Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):104B-113B.
    View in: PubMed
    Score: 0.004
  160. Clinical features and diagnosis of venous thrombosis. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):114B-127B.
    View in: PubMed
    Score: 0.004
  161. Diagnosis of pulmonary embolism. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):128B-136B.
    View in: PubMed
    Score: 0.004
  162. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72.
    View in: PubMed
    Score: 0.004
  163. Duration of warfarin in pulmonary embolism. Chest. 2006 Jul; 130(1):299; author reply 299-300.
    View in: PubMed
    Score: 0.004
  164. Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am. 1986 Jan; 68(1):146-50.
    View in: PubMed
    Score: 0.003
  165. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006 Jan; 129(1):174-81.
    View in: PubMed
    Score: 0.003
  166. Methodological guidelines for clinical trials evaluating new therapeutic approaches in bone and joint surgery. J Bone Joint Surg Am. 1985 Oct; 67(8):1294-7.
    View in: PubMed
    Score: 0.003
  167. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):287S-310S.
    View in: PubMed
    Score: 0.003
  168. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004 Jun 01; 140(11):867-73.
    View in: PubMed
    Score: 0.003
  169. Chemical (VX) terrorist threat: public knowledge, attitudes, and responses. Biosecur Bioterror. 2004; 2(3):224-8.
    View in: PubMed
    Score: 0.003
  170. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003 Nov; 74(3):161-9.
    View in: PubMed
    Score: 0.003
  171. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30; 349(18):1695-702.
    View in: PubMed
    Score: 0.003
  172. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983 Jun; 98(6):891-9.
    View in: PubMed
    Score: 0.003
  173. Long-term anticoagulant therapy prevents recurrent venous thromboembolism. J R Soc Med. 1982 Apr; 75(4):289.
    View in: PubMed
    Score: 0.003
  174. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8.
    View in: PubMed
    Score: 0.002
  175. Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S.
    View in: PubMed
    Score: 0.002
  176. Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13.
    View in: PubMed
    Score: 0.002
  177. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. 2000 Feb 01; 132(3):227-32.
    View in: PubMed
    Score: 0.002
  178. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36.
    View in: PubMed
    Score: 0.002
  179. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol. 2000 Jan-Feb; 22(1):55-61.
    View in: PubMed
    Score: 0.002
  180. Drug-induced thrombocytopenia. Curr Opin Hematol. 1999 Sep; 6(5):349-53.
    View in: PubMed
    Score: 0.002
  181. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med. 1999 Sep; 160(3):1043-66.
    View in: PubMed
    Score: 0.002
  182. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999 Jan 25; 159(2):137-41.
    View in: PubMed
    Score: 0.002
  183. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998 Dec 01; 129(11):886-90.
    View in: PubMed
    Score: 0.002
  184. Hemorrhagic complications of anticoagulant treatment. Chest. 1998 Nov; 114(5 Suppl):511S-523S.
    View in: PubMed
    Score: 0.002
  185. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 Sep 28; 158(17):1909-12.
    View in: PubMed
    Score: 0.002
  186. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
    View in: PubMed
    Score: 0.002
  187. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997 Dec 8-22; 157(22):2562-8.
    View in: PubMed
    Score: 0.002
  188. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med. 1997 Nov 10; 157(20):2317-21.
    View in: PubMed
    Score: 0.002
  189. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94.
    View in: PubMed
    Score: 0.002
  190. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303.
    View in: PubMed
    Score: 0.002
  191. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 Jul 01; 88(1):3-40.
    View in: PubMed
    Score: 0.002
  192. Hemorrhagic complications of anticoagulant treatment. Chest. 1995 Oct; 108(4 Suppl):276S-290S.
    View in: PubMed
    Score: 0.002
  193. The low-probability lung scan. A need for change in nomenclature. Arch Intern Med. 1995 Sep 25; 155(17):1845-51.
    View in: PubMed
    Score: 0.002
  194. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61.
    View in: PubMed
    Score: 0.002
  195. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med. 1994 May 09; 154(9):999-1004.
    View in: PubMed
    Score: 0.002
  196. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. 1994 Feb 14; 154(3):289-97.
    View in: PubMed
    Score: 0.001
  197. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6.
    View in: PubMed
    Score: 0.001
  198. Duplex ultrasonography for the detection of deep vein thrombi after total hip or knee arthroplasty. Angiology. 1993 Jan; 44(1):26-33.
    View in: PubMed
    Score: 0.001
  199. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992 Aug; 152(8):1589-95.
    View in: PubMed
    Score: 0.001
  200. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992 Apr 09; 326(15):975-82.
    View in: PubMed
    Score: 0.001
  201. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 03; 322(18):1260-4.
    View in: PubMed
    Score: 0.001
  202. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA. 1990 May 02; 263(17):2313-7.
    View in: PubMed
    Score: 0.001
  203. Serial impedance plethysmography in pregnant patients with clinically suspected deep-vein thrombosis. Clinical validity of negative findings. Ann Intern Med. 1990 May 01; 112(9):663-7.
    View in: PubMed
    Score: 0.001
  204. Predicting the daily prothrombin time response to warfarin. Ther Drug Monit. 1990 May; 12(3):246-9.
    View in: PubMed
    Score: 0.001
  205. Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest. 1990 Jan; 97(1):23-6.
    View in: PubMed
    Score: 0.001
  206. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med. 1989 Nov; 149(11):2549-55.
    View in: PubMed
    Score: 0.001
  207. Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol. 1989 Oct; 29(10):896-900.
    View in: PubMed
    Score: 0.001
  208. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1989 Feb; 95(2 Suppl):26S-36S.
    View in: PubMed
    Score: 0.001
  209. The current status and future directions of impedance cardiography in ICU. Ann Biomed Eng. 1989; 17(5):483-94.
    View in: PubMed
    Score: 0.001
  210. Pulmonary embolism in outpatients with pleuritic chest pain. Arch Intern Med. 1988 Apr; 148(4):838-44.
    View in: PubMed
    Score: 0.001
  211. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986 Oct 30; 315(18):1109-14.
    View in: PubMed
    Score: 0.001
  212. Prophylaxis of venous thromboembolism. An overview. Chest. 1986 May; 89(5 Suppl):374S-383S.
    View in: PubMed
    Score: 0.001
  213. The diagnosis of clinically suspected pulmonary embolism. Practical approaches. Chest. 1986 May; 89(5 Suppl):417S-425S.
    View in: PubMed
    Score: 0.001
  214. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1986 Feb; 89(2 Suppl):16S-25S.
    View in: PubMed
    Score: 0.001
  215. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985 Dec; 88(6):819-28.
    View in: PubMed
    Score: 0.001
  216. Risk of haemorrhage associated with long term anticoagulant therapy. Drugs. 1985 Nov; 30(5):444-60.
    View in: PubMed
    Score: 0.001
  217. The diagnosis of clinically suspected venous thrombosis. Clin Chest Med. 1984 Sep; 5(3):439-56.
    View in: PubMed
    Score: 0.001
  218. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA. 1984 Jul 13; 252(2):235-9.
    View in: PubMed
    Score: 0.001
  219. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.